Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K31/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/233437USE OF DIKETONE COMPOUND IN PHOTODYNAMIC THERAPY OR DIAGNOSIS
WO 26.11.2020
Int.Class A61K 31/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
12Ketones
Appl.No PCT/CN2020/089628 Applicant BEIJING WHOLESOMETECH CO., LTD. Inventor JIAO, Ning
The present invention belongs to the technical field of medicine, and relates to use of a diketone compound in photodynamic therapy or diagnosis. In particular, the present invention relates to use of a compound as shown in formula (I), a pharmaceutically acceptable salt or ester thereof, a prodrug, a stereoisomer, a hydrate, a solvate, a crystal form, metabolite forms thereof, or any combination or mixture thereof in the preparation of a medicament or a reagent. The medicament or the reagent is used for photodynamic therapy or photodynamic diagnosis of diseases, or is used for skin beauty by means of photodynamic therapy.
2.WO/2020/235587TANDOSPIRONE DERIVATIVE
WO 26.11.2020
Int.Class C07D 209/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
209Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
56Ring systems containing three or more rings
58- or -condensed
724,7-Endo-alkylene-iso-indoles
76with oxygen atoms in positions 1 and 3
Appl.No PCT/JP2020/019911 Applicant NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA Inventor KONDO Takashi
A compound represented by formula (1) or a pharmaceutically acceptable salt thereof can be used as an active ingredient of a drug for central nervous system diseases or as a candidate compound for a precursor of said active ingredient. In formula (1), R1, R2, and R3 each independently represent a substance selected from the group consisting of a hydrogen atom, a hydroxy group, and an alkoxy group having 1-6 carbon atoms, and at least one of R1, R2, and R3 is a hydroxy group.
3.WO/2020/235727COMPOSITION FOR SKIN WHITENING COMPRISING FRACTION OF INULA HELENIUM EXTRACT OR COMPOUND ISOLATED THEREFROM AS ACTIVE INGREDIENT
WO 26.11.2020
Int.Class A61K 8/9789
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
8Cosmetics or similar toilet preparations
18characterised by the composition
96containing materials, or derivatives thereof, of undetermined constitution
97from algae, fungi, lichens or plants; from derivatives thereof
9783Angiosperms
9789Magnoliopsida
Appl.No PCT/KR2019/006211 Applicant SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION Inventor KIM, Yeong Shik
The present invention relates to a cosmetic composition for skin whitening comprising a hexane fraction of an Inula helenium extract, or an alantolactone or isoalantolactone compound isolated therefrom as an active ingredient. The fraction or compound according to the present invention inhibits melanin synthesis, and the compound of the present invention exhibits an effect of inhibiting mRNA or protein expression of a microphthalmia-associated transcription factor (MITF) which is a melanin synthesis promoting factor, tyrosinase, tyrosinase related protein 1, or tyrosinase related protein 2, and thus can be effectively used as a cosmetic composition for skin whitening, a pharmaceutical composition, or a functional health food.
4.WO/2020/235967COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING AUTOIMMUNE DISEASES
WO 26.11.2020
Int.Class A61K 31/569
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
565not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
568substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
569substituted in position 17 alpha, e.g. ethisterone
Appl.No PCT/KR2020/006714 Applicant INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY Inventor LEE, Eun Jig
The present invention relates to a composition for preventing, alleviating or treating autoimmune diseases. The composition of the present invention not only suppresses the expression level of transcription factor proteins involved in induction of differentiation of orbital fibroblasts, but also significantly reduces the expression level of inflammatory cytokines, thereby very effectively inhibiting the differentiation of orbital fibroblasts. Thus, the composition of the present invention can be very effectively applied to the prevention, alleviation or treatment of autoimmune diseases, for example, Graves' orbitopathy.
5.20200367492TREATMENT COMPOSITIONS PROVIDING AN ANTIMICROBIAL BENEFIT
US 26.11.2020
Int.Class A01N 37/36
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
37Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
36containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio-analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids
Appl.No 16989303 Applicant Reckitt Benckiser LLC Inventor Avinash BUDHIAN

Treatment compositions which may be use to impart an antimicrobial benefit to animate and inanimate surfaces, e.g, topical compositions and hard surface and soft surface treatment compositions comprising specific surfactant comprising anionic surfactants, or anionic and nonionic surfactant systems.

6.20200368152LIQUID DEPOT FOR NON-INVASIVE SUSTAINED DELIVERY OF AGENTS TO THE EYE
US 26.11.2020
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
Appl.No 16909242 Applicant IDROP, INC Inventor Vernon G. Wong

The present embodiments provide compositions, methods, and kits for the treatment or prevention of ocular conditions or maladies via non-invasive liquid depots. In at least one embodiment, the liquid depot is capable of sustained-release delivery of at least one pharmaceutical agent to the eye for days or weeks.

7.20200368162Nucleic Acid-Based Therapy of Muscular Dystrophies
US 26.11.2020
Int.Class A61K 9/127
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
127Liposomes
Appl.No 16487734 Applicant ModernaTX, Inc. Inventor Paolo Martini

The invention related to polynucleotides comprising an open reading frame of linked nucleosides encoding therapeutic proteins or variant therapeutic proteins, isoforms thereof, functional fragments thereof, and fusion proteins comprising therapeutic proteins. In some embodiments, the open reading frame is sequence-optimized. The invention also relates to methods of treating muscular dystrophies.

8.20200368222METHODS OF TREATING RADIATION INDUCED GASTROINTESTINAL SYNDROME (RIGS) AND RELATED DISEASE STATES USING YEL002/BCN057
US 26.11.2020
Int.Class A61K 31/4704
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
47042-Quinolinones, e.g. carbostyril
Appl.No 16870864 Applicant University of Kansas Inventor Subhrajit Saha

The present disclosure is directed to method of treatment for treating or ameliorating various conditions caused by radiation exposure such as RIGS, enteritis, oral mucositis, mucositis, and proctitis by the administration of a compound Yel002/BCN057 or an analog thereof.

9.20200368242USE OF TG02 FOR TREATING GLIOMAS IN PEDIATRIC SUBJECTS
US 26.11.2020
Int.Class A61K 31/519
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
Appl.No 16991863 Applicant UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION Inventor Sameer AGNIHOTRI

The present disclosure relates to uses of TG02, for treating a glioma in a pediatric human subject. In certain embodiments, the glioma can be a pediatric high-grade glioma (PHGG), e.g., a diffuse intrinsic pontine glioma (DIPG), and/or a H3.3-mutated glioma (e.g., a H3K27M-mutated glioma). The present disclosure further provides pharmaceutical compositions and kits that include an ERK5 inhibitor.

10.20200368262Use of Timosaponin Enzymatically Transformed Product in Preparation of Drugs for Inhibiting Skin Superficial Fungi
US 26.11.2020
Int.Class A61K 31/7048
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7048having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
Appl.No 16848708 Applicant Shanghai University of Traditional Chinese Medicine Inventor Tong ZHANG

The present disclosure provides use of a timosaponin enzymatically transformed product in preparation of drugs for inhibiting skin superficial fungi. In the use provided in the present disclosure, the timosaponin enzymatically transformed product is prepared by enzymatically transforming rhizoma anemarrhenae extract with β-glucosidase or a compound enzyme of xylanase and cellulose after purification. In the present disclosure, as an active pharmaceutical ingredient for inhibiting skin superficial fungi, the timosaponin enzymatically transformed product has the minimum inhibitory concentration of 4 mg/L against fungi, which is obviously superior to total timosaponin in the bacteriostatic capability, and has a certain application prospect in the aspect of treating skin superficial mycoses.